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ABSTRACT
Prokaryotic transcriptional regulatory elements
have been adopted for controlled expression of
cloned genes in mammalian cells and animals, the
cornerstone for gene-function correlations, drug
discovery, biopharmaceutical manufacturing as well
as advanced gene therapy and tissue engineering.
Many prokaryotes have evolved speci®c molecular
communication systems known as quorum-sensing
to coordinate population-wide responses to physio-
logical and/or physicochemical signals. A generic
bacterial quorum-sensing system is based on a
diffusible signal molecule that prevents binding of a
repressor to corresponding operator sites thus
resulting in derepression of a target regulon. In
Streptomyces, a family of butyrolactones and their
corresponding receptor proteins, serve as quorum-
sensing systems that control morphological devel-
opment and antibiotic biosynthesis. Fusion of the
Streptomyces coelicolor quorum-sensing receptor
(ScbR) to a eukaryotic transactivation domain
(VP16) created a mammalian transactivator (SCA)
which binds and adjusts transcription from chimeric
promoters containing an SCA-speci®c operator
module (PSPA). Expression of erythropoietin or the
human secreted alkaline phosphatase (SEAP) by
this quorum-sensor-regulated gene expression sys-
tem (QuoRex) could be ®ne-tuned by non-toxic
butyrolactones in a variety of mammalian cells
including human primary and mouse embryonic
stem cells. Following intraperitoneal implantation of
microencapsulated Chinese hamster ovary cells
transgenic for QuoRex-controlled SEAP expression
into mice, the serum levels of this model glyco-
protein could be adjusted to desired concentrations
using different butyrolactone dosing regimes.
INTRODUCTION
Integrated molecular interventions in mammalian cells and
animals which require precisely adjusted expression of desired
transgenes (1) have fostered recent advances in prototype gene
therapy scenarios (2), drug discovery (3), biopharmaceutical
manufacturing (4,5), gene-function analysis (6±8) and the
design of animal models mimicking prominent human disease
phenotypes (7).
In recent years, a variety of heterologous transgene control
systems have been designed for use in mammalian cells and
transgenic animals (1,9). Most modulate target gene tran-
scription in response to antibiotics (10±12), immunosuppres-
sive agents (13) or steroid hormones and their analogs (14,15).
Although well established in basic research, ongoing concerns
about low or leaky expression, promotion of antibiotic
resistance, dif®culties in managing the levels of regulating
chemicals and interference of inducers with host regulatory
networks may jeopardize long-term use of current gene
control arrangements in human therapy and substantiate the
need for gene regulation systems responsive to a new class of
molecules (16±18).
Quorum-sensing systems regulate prokaryotic gene expres-
sion in response to ¯uctuations in cell-population density.
Quorum-sensing bacteria produce and release chemical signal
molecules and communicate within and across species to
regulate a diverse array of activities including symbiosis,
virulence, competence, conjugation, motility, sporulation,
bio®lm formation and antibiotic production (19,20). In
Streptomyces, a family of related butyrolactones and their
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corresponding receptor proteins serve as quorum-sensing
systems to coordinate morphological development and anti-
biotic biosynthesis (20,21).
Here we report the use of Streptomyces coelicolor and
Streptomyces pristinaespiralis butyrolactone-responsive
quorum-sensing systems to adjust transgene expression in
mammalian cells and mice. The use of quorum-sensing
pheromones in vivo did not elicit prominent side effects
suggesting that butyrolactones are safe inducers. Since most
bacterial species are endowed with a speci®c quorum-sensing
system (19,22), Streptomyces-derived QuoRex technology is a
promising prototype of a new mammalian gene control system
using an alternative class of inducing molecules.
MATERIALS AND METHODS
Synthesis and formulation of SCB1 and MP133
Racemic 2-(1¢-hydroxy-6-methylheptyl)-3-(hydroxymethyl)-
butanolide (SCB1) was synthesized as depicted in Figure 1A.
The butanolide (2) was formed by the reduction of diethyl
formylsuccinate (1) (23) with NaBH4, and the hydroxyl group
of this butanolide was subsequently protected with a
trimethylsilyl ether (24). The alkyl chain of SCB1 was
synthesized starting from diethyl malonate and 1-bromo-4-
methylpentane (25), which resulted in a 42% (w/w) yield of
6-methylheptanoic acid (4) over three steps. The acid was
converted into its acid chloride with thionyl chloride and
attached to 3-(trimetylsilyloxymethyl)-butanolide (3) using
lithium diisopropylamine in dry tetrahydrofuran. After
removal of the trimethylsilyl group, racemic 2-(6-methyl-
heptanoyl)-3-(hydroxymethyl)-butanolide (5) or A-factor was
obtained. The reduction of the ketone carbonyl group of 5 with
NaBH4 and separation by preparative C18 reversed-phase
HPLC resulted in racemic mixtures of the diastereoisomers of
SCB1 (6). Diastereomers were over 99% pure as assessed by
HPLC, and NMR-based analysis revealed no cross contam-
ination by other diastereomers. A detailed protocol for
the synthesis of SCB1 is provided at http://www.biotech.biol.
ethz.ch/martinf/download/QuoRex.zip.
Synthesis of 4-methyl-3-pentyl-2(5H)-furanone (MP133) is
shown in Figure 1B. Two synthetic pathways were designed
for MP133. Whereas the ®rst strategy follows Demnitz's
approach to furanones (26), the second protocol is analogous
to the preparation of some furanones which naturally occur in
Streptomyces antibioticus (27). According to the synthesis by
Grossmann and SeÂquin (27), the readily available methylated
furanone (7) was condensed with pentanal. Subsequent
deprotection with BBr3 followed by NaBH4-reduction resulted
in a racemate (8). This racemate was then tosylated at the side
chain hydroxy group, and the tosylate obtained reduced with
NaBH4 to give MP133 (9). Supplementary information on
the synthesis of MP133 is available at http://www.biotech.
biol.ethz.ch/martinf/download/QuoRex.zip.
SCB1 and MP133 were dissolved in DMSO at 100 mg/ml
and diluted to reach a ®nal DMSO concentration of 0.1% (v/v)
in all cell culture experiments. Both butyrolactones were used
at a concentration of 10 mg/ml unless stated otherwise.
Plasmid construction
The S.coelicolor-derived butyrolactone-dependent transacti-
vator SCA (ScbR-VP16) was constructed by PCR-mediated
ampli®cation of scbR from S.coelicolor A3(2) scbR using
oligonucleotides OWW36 (5¢-gtacgaattcccaccatggccaagcag-
gaccgggcg-3¢) and OWW37 (5¢-gcgcgcggctgtacgcg-
gagtccttcccggtcggtgccagtt-3¢) followed by cloning (EcoRI/
BssHII) into pWW35 (10), thereby resulting in pWW122.
Similarly, the S.pristinaespiralis-derived transactivator SPA
(SpbR-VP16) was designed by cloning PCR-ampli®ed
[oligonucleotides OWW34 (5¢-gtacgaattcccaccatggcgcggcag-
gagcgg-3¢) and OWW35 (5¢- gcgcgcggctgtacgcggagtggg-
cggcgggctggg-3¢)] spbR from S.pristinaespiralis (strain
NRRL2958) EcoRI/BssHII into pWW35 to give pWW123.
SCA- and SPA-responsive promoters [PSCA (OscbR-PhCMVmin);
PSPA (OpapRI-PhCMVmin)] were assembled by amplifying
PhCMVmin-encoding fragments from pRevTre (Clontech, Palo
Alto, CA) with OWW39 (5¢-gatcgacgtcgccattgaaaaccgaccgtg-
ccgtttttttcctgcaggtcgagctcggtacccgggtc-3¢; OpapRI site under-
lined) and OWW22 (10) as well as OWW49 (5¢-gatcgacg-
tctaagatacagactgagcggtttttttcctgcaggtcgagctcggtacccgggtc-3¢;
OscbR site underlined) and OWW22 (10), respectively. The
PSCA and PSPA-encoding fragments were cloned (AatII/EcoRI)
into pWW36 (10) to result in plasmids pWW124 (PSCA-
SEAP-pA) and pWW135 (PSPA-SEAP-pA), respectively. The
EPO expression vector pWW156 (PSPA-EPO-pA) was con-
structed by EcoRI/XhoI-mediated swapping of SEAP
(pWW135) with EPO encoded by pMF242 (10±12). The
SCA-encoding retroviral vector pWW158 was constructed by
excising SCA (EcoRI/BamHI) from pWW122 and cloning it
(EcoRI/BglII) into pMSCVneo (Clontech). pWW122-derived
retroviruses were produced following Clontech's protocol and
used for transduction of CHO-K1. The bacterial scbR
expression vector pWW314 (Pn-scbR-his6-pA) was con-
structed by PCR-mediated ampli®cation of scbR from
pWW122 using primers OWW304 (5¢- cggaattcccaccatgca-
tatggccaagcagg accgggc-3¢) and OWW305 (5¢-gctctagag-
caagcttttaatggtgatggtgatgatgggatccacgcggaaccagaccgtccttccc-
ggtcggtgcca-3¢) followed by cloning (NdeI/HindIII) into
pRSETmod (Weber,C.C., Link,N., Fux,C., Zisch,A.H.,
Weber,W. and Fussenegger,M., submitted for publication).
Plasmid pWW56 has been described previously (10).
Gel retardation assays
PSCA- and PSPA-encoding probes were generated by PCR
using plasmids pWW124 and pWW135 as templates,
[32P]dATP and primers OWWF (5¢-ggttccgccacatttcccc-3¢)
and OWWR (5¢-aagctgactctagaggatcc-3¢). Escherichia coli
XL1-Blue (Stratagene, La Jolla, CA) were transformed with
pWW314 and grown in LB to an OD600 of 0.6 prior to
induction of scbR with 1 mM IPTG for 3 h. Transgenic E.coli
were collected by centrifugation and disrupted in TA buffer
[10 mM Tris (pH 7.5), 10 mM MgCl2, 1 mM EDTA, 1 mM
DTT, 0.1% (w/v) Triton X-100, 50 mM NaCl]. Crude protein
extract (10 mg) was incubated with SCB1 for 10 min in the
presence of 2 mg of competitor DNA [poly(dI±dC)´(dI±dC)]
and then mixed with the probe. Protein±DNA complexes were
resolved on 5% (w/v) polyacrylamide-TBE [90 mM Tris,
90 mM borate, 2 mM EDTA (pH 8)] gels, run at room
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temperature and constant voltage (7 V cm±1) for 2 h, dried and
visualized by autoradiography.
Cell culture, transfection, stable cell lines and reporter
gene assays
Chinese hamster ovary cells (CHO-K1, ATTC CCL-61) were
cultured in FMX-8 complete medium (FMX-8; Cell Culture
Technology, ZuÈrich, Switzerland) supplemented with 10%
(v/v) FCS and 1% (v/v) of a penicillin/streptomycin solution
(cat. no. P4458; Sigma, St Louis, MO), African green monkey
kidney cells (COS-7, ATCC CRL-1651), human embryonic
kidney cells [HEK293-T (28)], baby hamster kidney cells
(BHK-21, ATCC CCL-10) and human hepatocellular carci-
noma cells (HepG2, ATCC HB-8065) were cultivated in
DMEM-complete medium [DMEM supplemented with 10%
(v/v) FCS and 1% (v/v) penicillin/streptomycin solution].
Human umbilical vein endothelial cells (HUVEC; Promocell,
Heidelberg, Germany) and mouse embryonic stem cells
(StemCell Technologies, Meylan, France) were cultivated
according to the suppliers' protocols.
Twelve hours prior to transfection, 60 000 CHO-K1 cells
were seeded per well of a 24-well plate. Plasmid DNA (1.2 mg
per well; if a cotransfection was made, equal amounts of each
plasmid were used) in 0.5 M CaCl2 (®nal volume: 12 ml) was
mixed with 12 ml of phosphate solution (50 mM HEPES,
pH 7.05, 280 mM NaCl, 1.5 mM Na2HPO4), vortexed for 5 s
and incubated for 25 s prior to addition of 0.4 ml of FMX-8
medium containing 2% (v/v) FCS. The culture medium was
replaced by the transfection mixture and cells were incubated
for 5 h prior to performing a 30 s glycerol shock [0.5 ml of 5%
(v/v) glycerol in FMX-8 medium containing 2% (v/v) FCS]
and one wash step (1 ml of FMX-8 complete medium). The
cells were cultivated in 0.5 ml of FMX-8-complete medium in
the presence and absence of the regulating butyrolactone until
reporter gene expression was quanti®ed.
For transfection of HEK293-T, COS-7, BHK-21 and
HepG2 cells, 120 000 cells were seed per well of a 12-well
plate containing 1 ml of DMEM complete medium and grown
for 12 h prior to transfection. Total plasmid DNA (0.6 mg) in
50 ml of 0.25 M CaCl2 was added dropwise to 50 ml of 23
HBS (100 mM HEPES, pH 7.1; 280 mM NaCl, 1.5 mM
Figure 1. Synthesis of SCB1 (A) and MP133 (B). More detailed information is provided at http://www.biotech.biol.ethz.ch/martinf/download/QuoRex.zip.
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Na2HPO4) while vortexing, followed by addition to the cells.
After a 4 h incubation time, the supernatant was removed and
the cells were washed once with pre-warmed DMEM
complete medium. Subsequently, the cells were cultured in
1 ml of DMEM complete medium per well in the presence or
absence of regulating butyrolactone until assessment of
reporter gene expression. Mouse ES cells (60 000 cells/well
of a 12-well plate) were transfected using FuGENE 6 (Roche
Molecular Biochemicals, Rotkreuz, Switzerland) according to
the suppliers instructions. The regulating butyrolactone was
added 4 h post-FuGENE 6-mediated transfection.
For HUVEC transfection, 300 000 cells were seeded per
well of a 6-well plate 12 h prior to transfection. Total plasmid
DNA (20 mg) in 150 ml of PBS (10 mM NaH2PO4, pH 7.4,
137 mM NaCl, 2.7 mM KCl) were mixed with 150 ml of
DEAE Dextran solution (0.83 mg/ml in PBS; cat. no. D9885;
Sigma). The cells were washed twice with PBS and incubated
with the transfection mix for 30 min at 37°C in a humidi®ed
atmosphere containing 5% (v/v) CO2-containing atmosphere
at 37°C. The plate was gently shaken every 10 min. After
30 min, 2 ml of medium (EC medium; Promocell, Heidelberg,
Germany) supplemented with 100 mM chloroquine (cat. no.
C6628; Sigma) was added to the cells followed by incubation
for another 2.5 h. The medium was removed and the cells were
treated with 1 ml of 9% (v/v) DMSO in EC medium for 90 s
followed by a washing step and incubation in the presence and
absence of the regulating butyrolactone for expression pro®l-
ing of the reporter gene.
The stable SCA production cell line CHO-SCA was
constructed by transducing CHO-K1 with pWW158-derived
retroviruses. For construction of the double transgenic cell line
CHO-SCA-SEAP, CHO-SCA1 was cotransfected with
pWW124 and pZeoSV2 (Invitrogen, Carlsbad, CA). Stable
cell lines were selected and maintained in culture medium
supplemented with appropriate antibiotics (400 mg/ml G418,
100 mg/ml zeocin). Mixed stable cell populations were cloned
using FACS-mediated single cell sorting (FACStarPlus;
Beckton Dickinson, San Jose, CA). For all analyses CHO-
SCA-SEAP was used at a density of 66 000 cells/ml. SEAP
and EPO expression were quanti®ed as described previously
(12). All data represent average values of three independent
transfections/cultures.
In vivo methods
Cells were encapsulated in alginate-poly-(L-lysine)-alginate
beads (alginate-PLL-alginate; 200 cells/per capsule, 2 3 106
cells/animal) as described previously and injected intra-
peritoneally into female OF1 mice (oncins france souche 1;
Iffa-Credo, Lyon, France) (10,29) obtained from Iffa-Credo.
One hour after capsule implantation, mice were injected with
different IM-2-SCB1 doses, diluted in 0.9% (w/v) NaCl from a
stock solution of 100 mg/ml in ethanol. Serum SEAP levels
were quanti®ed from at least eight mice per dose as described
(29, Fux,C., Weber,W. and Fussenegger,M., submitted for
publication). All experiments involving animals were ap-
proved by the French Ministry of Agriculture and Fishery
(Paris, France) and performed by M.D.E. at the Institut
Universitaire de Technologie, IUTA, F-69622 Villeurbanne
Cedex, France.
RESULTS
Design of a mammalian transcription control system
based on Streptomyces quorum-sensing components
Exploiting molecular design concepts of the butyrolactone
quorum-sensing system which evolved in Streptomyces to
control antibiotic biosynthesis and/or coordinate morpho-
logical differentiation, we have constructed binary mamma-
lian transcription control units called the quorum-sensor-
regulated gene expression system (QuoRex). The receptors of
the S.coelicolor [ScbR; S.coelicolor butyrolactone transcrip-
tional repressor; (30)] and S.pristinaespiralis [SpbR;
S.pristinaespiralis butyrolactone transcriptional repressor
(21)] butyrolactone quorum-sensing systems were each
fused to the Herpes simplex virus-1 (HSV-1)-derived mam-
malian transactivation domain VP16 (31) thus creating the
arti®cial mammalian transactivators SCA (ScbR-VP16) and
SPA (SpbR-VP16) (Fig. 2). The SCA/SPA-speci®c mam-
malian promoters PSCA/PSPA were assembled by cloning the
ScbR-/SpbR-speci®c operator modules OscbR/OpapRI 5¢ of a
minimal human cytomegalovirus immediate early promoter
(PhCMVmin, Fig. 2). Cotransfection of the SCA/SPA expression
vectors with plasmids encoding PSCA- and PSPA-driven human
secreted alkaline phosphatase (SEAP) into CHO-K1 cells
resulted in high SEAP expression levels (21.7 6 2.7 U/l for
SCA/PSCA-SEAP-pA and 29.6 6 3.5 U/l for SPA/PSPA-SEAP-
pA) which were comparable to those of a PSV40-driven SEAP
control construct (pWW56; PSV40-SEAP-pA) (46.8 6 6.7
U/l). Since the S.coelicolor and S.pristinaespiralis butyrolac-
tone quorum-sensing systems are highly homologous, their
derived mammalian transcription control units recognize the
same operator sites in CHO-K1 cells: SCA binds and activates
transcription from PSPA (85.8 6 5.8 U/l for SCA/PSPA-SEAP-
pA) and SPA promotes PSCA-driven expression (36.0 6 2.2
U/l for SPA/PSCA-SEAP-pA). These ®ndings demonstrate that
the Streptomyces quorum-sensing components ScbR/OscbR
and SpbR/OpapRI retain their speci®c (cross)interaction and
form a potent heterologous transcription unit in mammalian
cells.
Butyrolactone responsiveness of QuoRex-controlled
transgene expression in mammalian cells
Expecting that SCA-PSCA, SCA-PSPA, SPA-PSCA and SPA-
PSPA interactions could be engineered for adjustable transgene
expression in mammalian cells by speci®c butyrolactone
derivatives, we have designed novel/re®ned protocols for the
synthesis of racemic SCB1 which elicits antibiotic production
in S.coelicolor (25,30) and MP133, a butenolide ®rst isolated
from S.antibioticus (32) (Fig. 1). The enantiomers of SCB1
were obtained as two racemic mixtures, IM-2 type SCB1 and
VB type SCB1 (IM-2-SCB1 and VB-SCB1).
In order to qualify as molecules for controlling transgene
expression in mammalian cells, SCB1 and MP133 should not
have any undesirable physiological impact on host cells. An
indicator for possible toxicity of SCB1 and MP133 is their
in¯uence on constitutive reporter gene expression. We have
therefore added increasing SCB1 and MP133 concentrations
to a CHO-K1 derivative engineered for constitutive SEAP
expression. Both butyrolactones showed no effect on
SEAP expression at concentrations up to 10 mg/ml. At a
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concentration of 100 mg/ml, both SCB1 and MP133 were
toxic/growth-retarding for mammalian cells as indicated by a
depression in SEAP expression levels which was more
prominent for both stereoisomers of SCB1 than for MP133
(Fig. 3A).
When used to adjust transient PSPA-driven SEAP expression
in CHO-K1 cells transfected with an SCA expression vector,
addition of increasing concentrations of SCB1 correlated with
decreasing SEAP production pro®les indicating that this
butyrolactone releases SCA from PSPA which terminated
transcriptional activation of SEAP expression (Fig. 3B).
However, the structurally related MP133 was unable to
modulate SEAP production signi®cantly within its non-toxic
concentration range. Interestingly, IM-2-SCB1 was more
ef®cient than VB-SCB1 in changing SCA's allostery to
prevent PSPA binding. This was illustrated by a progressive
IM-2-SCB1-mediated decrease of SEAP activity reaching
basal expression at 10 mg/ml corresponding to 1.9% of fully
induced expression. In contrast, addition of VB-SCB1 reduced
expression of this human glycoprotein only to half-maximum
levels at this concentration (Fig. 3B). The remarkable
stereoselective discrimination of SCA between the two
SCB1 diastereomers emphasizes the speci®city of quorum-
sensing phenomena. IM-2-SCB1 retained its excellent
regulation performance in an isogenic QuoRex-controlled
erythropoietin expression setting (PSPA-EPO-pA; ±IM-2-
SCB1: 690 6 28 mIU/ml; +IM-2-SCB1: 23.7 6 5.2 mIU/ml).
In contrast to SCA-dependent transactivation of target
promoters, neither SCB1 nor MP133 were able to disrupt
SPA-PSPA or SPA-PSCA interactions suggesting that SCB1 is
Figure 2. Design and function of the quorum-sensor-derived mammalian
gene regulation system (QuoRex). (A) Diagram of QuoRex' genetic
elements: the butyrolactone-dependent transactivators SCA and SPA were
assembled by fusing the S.coelicolor/S.pristinaespiralis quorum-sensing
receptors ScbR/SpbR 3¢ to the Herpes simplex virus 1 (HSV-1)-derived
mammalian transactivation domain. SCA and SPA were cloned into a
constitutive mammalian expression con®guration (pWW122/pWW123)
driven by the simian virus 40 promoter (PSV40) and terminated by an
SV40-derived polyadenylation site (pA). SCA/SPA-speci®c promoters were
constructed by cloning the ScbR-/SpbR-speci®c operator modules
(OscbR/OpapRI) adjacent to a minimal version of the human cytomegalovirus
immediate early promoter (PhCMVmin). (B) In the absence of regulating
butyrolactones (±SCB1), the transactivator (SCA) binds to its cognate
PSCA/PSPA promoters and initiates transcription of the cloned gene of
interest (goi). However, addition of SCB1 (+SCB1) results in disruption of
the SCA-PSCA/PSPA interactions and repression of goi.
Figure 3. Impact of butyrolactone ligands on constitutive and QuoRex-
controlled gene expression in CHO-K1. (A) Effect of the SCB1 diaster-
eomers IM-2-SCB1 and VB-SCB1 as well as MP133 on constitutive SEAP
expression in CHO-K1. Triplicate CHO-K1 cultures were transfected with a
PSV40-driven SEAP expression vector (pWW56) and grown for 48 h at the
indicated ligand concentrations prior to quanti®cation of SEAP in the
culture medium. (B) Modulation of PSPA-driven SEAP expression in
CHO-K1 cells transiently transfected with pWW122 (PSV40-SCA-pA) and
pWW124 (PSPA-SEAP-pA) following addition of different IM-2-SCB1,
VB-SCB1 and MP133 concentrations. SEAP assays were performed 48 h
post-transfection (all assays in triplicate).
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speci®c for SCA (in vitro and in vivo; data not shown).
Thus, SPA awaits isolation and characterization of SpbR-
speci®c butyrolactones before implementation of the
S.pristinaespiralis-derived mammalian gene regulation sys-
tem can proceed (20).
DNA-binding speci®city of SCA
The regulatory activity of SCA for promoters PSCA and PSPA
was analyzed following cotransfection of pWW122 (PSV40-
SCA-pA) with either pWW135 (PSCA-SEAP-pA) or pWW124
(PSPA-SEAP-pA) into CHO-K1. Surprisingly, SCA activated
the promoter containing the heterologous operator sequence
(OpapRI) more ef®ciently than the same promoter with its
cognate operator (OscbR). At all IM-2-SCB1 concentrations
tested (0±100 mg/ml), the SCA-PSCA con®guration only
reached approximately one-third of the SEAP expression
levels compared to the heterologous SCA-PSPA combination
(Fig. 4A).
In order to investigate whether variations in expression
levels were associated with different af®nities of SCA for
PSCA and PSPA, in vitro-formed SCA-PSCA and SCA-PSPA
complexes incubated at increasing IM-2-SCB1 concentrations
were resolved on polyacrylamide gels. These gel retardation
assays provided biochemical evidence that SCA did indeed
have higher af®nity for the heterologous PSPA than for PSCA
which apparently renders the SCA-PSPA con®guration more
effective for controlling transgene expression in mammalian
cells (Fig. 4B).
Detailed expression analysis of the SCA-PSPA-based
QuoRex system
The performance of the SCA-PSPA-based QuoRex system was
evaluated in a variety of mammalian cell types including
human primary cells and mouse embryonic stem cells. To this
end, we cotransfected the SCA expression vector pWW122
(PSV40-SCA-pA) and the SCA-responsive SEAP expression
vector pWW124 (PSPA-SEAP-pA) into different cell lines and
assayed the SEAP levels in their culture supernatants follow-
ing cultivation for 48 h in the presence and absence of IM-2-
SCB1. In all cell lines tested, high SEAP expression could be
monitored in the absence of IM-2-SCB1 whereas complete
repression was achieved following addition of this butyro-
lactone (Table 1).
We also evaluated QuoRex's key regulation characteristics
(dose-dependence, expression kinetics and reversibility) in a
stable expression con®guration. QuoRex was engineered into
CHO-K1 cells following a two step procedure. The SCA
expression unit was transduced using a transgenic retrovirus
(5¢LTR-y+-SCA-PPGK-neoR-3¢LTR) and individual CHO-K1-
derived cell clones were assessed for QuoRex performance
after transient transfection with the PSPA-driven SEAP
expression construct pWW124. The regulation performance
of four independent CHO-SCA clones in the presence and
absence of IM-2-SCB1 is shown in Table 2. Because of its
balanced expression pro®les combining high maximum SEAP
expression levels as well as tight repression, we chose CHO-
SCA35 for further studies. The PSPA-driven SEAP expression
unit was stably integrated into CHO-SCA35 and individual
clones were scored for their regulation performance in the
presence and absence of IM-2-SCB1. Table 2 shows four
different double transgenic clones of which CHO-SCA35-
SEAP16 was chosen for further analysis.
Figure 4. Speci®city and af®nity of SCA for S.coelicolor/S.pristinaespiralis
OscbR/OpapRI operator modules. (A) SCA-dependent SEAP expression levels
driven by PSPA/PSCA promoters in CHO-K1 cells in the presence of different
IM-2-SCB1 concentrations. CHO-K1 cells were cotransfected with the SCA
expression plasmid pWW122 (PSV40-SCA-pA) and the SCA-dependent
SEAP expression vector pWW124/pWW135 (PSPA-SEAP-pA/PSCA-SEAP-
pA). Transfected cell lines were grown for 48 h in medium containing the
indicated IM-2-SCB1 concentrations prior to quanti®cation of SEAP expres-
sion levels. (B) Gel retardation assays showing interactions of ScbR with
OscbR and ScbR with OpapRI. The ScbR and radioactively labeled OscbR and
OpapRI protein±DNA complexes were incubated with various IM-2-SCB1
concentrations and resolved on a polyacrylamide gel. ScbR is released from
OscbR at lower IM-2-SCB1 concentrations compared to OpapRI indicating
higher af®nity of this S.coelicolor quorum-sensing receptor for
S.pristinaespiralis OpapRI than for its autologous OscbR.
Table 1. Expression characteristics of SCA/PSPA-driven secreted alkaline
phosphatase in different cell lines in the presence and absence of IM-2-
SCB1
Cell line ±IM-2-SCB1 +IM-2-SCB1
CHO-K1 60.4 6 8.3 1.81 6 0.17
BHK-21 5.0 6 0.4 0.23 6 0.04
COS-7 7.5 6 0.5 0.14 6 0.04
HEK 293-T 228.0 6 7.6 33.5 6 0.11
Hep G2 2.1 6 0.1 0.096 6 0.035
HUVEC 0.5 6 0.08 0.0001 6 0.0001
Mouse ES 1.0 6 0.02 0.027 6 0.007
Cells were transfected with plasmids pWW122 (PSV40-SCA-pA) and
pWW124 (PSPA-SEAP-pA) and grown for 48 h in the presence (10 mg/ml)
and absence of IM-2-SCB1 before scoring of SEAP production (in U/l).
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Upon exposure of CHO-SCA35-SEAP16 to increasing IM-2-
SCB1 concentrations, SEAP expression could be adjusted to
intermediate levels until it was completely repressed to
detection limits when the butyrolactone concentration reached
0.5 mg/ml (Fig. 5A). Interestingly, the sensitivity of CHO-
SCA35-SEAP16 to IM-2-SCB1 was one order of magnitude
higher compared to transient transfections, a phenomenon
which has previously been reported for double-transgenic cell
lines harboring the tetracycline-response gene regulation
system (33).
SEAP expression kinetics of CHO-SCA35-SEAP16 grown
in the presence of 0.5 mg/ml IM-2-SCB1 or in the absence of
this regulating butyrolactone were monitored for 48 h
(Fig. 5B). Despite its excellent regulation pro®les, high
expression levels in the absence of IM-2-SCB1 and tight
repression in its presence, the QuoRex system proved to be
completely reversible following repeated cycles of addition
and withdrawal of IM-2-SCB1 from the culture for a period of
over 140 h (Fig. 5C).
In vivo quorum-sensing-responsive gene expression
Following successful validation of QuoRex-controlled gene
expression in mammalian cells, we assessed its potential for
adjustable transgene expression in vivo. Mimicking current
gene therapy scenarios, we implanted CHO-SCA35-SEAP16
cells, encapsulated in biocompatible alginate-PLL-alginate
beads, intraperitoneally into immunocompetent mice.
Microencapsulation protects implanted cells from the mouse
immune system and prevents any in¯ammatory response as
well as the elimination of transgenic cells. Microencapsulated
cells remained responsive to IM-2-SCB1 as this butyrolactone
can diffuse through the alginate-PLL-alginate layers and
SEAP, a model for therapeutic proteins, was secreted across
the capsule (Fig. 6A). Following intraperitoneal implantation
of the same in vitro-validated cell batch, the mice received
different IM-2-SCB1 doses by injection (0±50 mg/kg). Serum
SEAP levels of treated mice were quanti®ed 72 h post-
implantation. IM-2-SCB1-adjustable SEAP production
including full repression to undetectable serum levels was
reached in these animals at butyrolactone concentrations
which showed no undesired effects on mouse physiology or
behavior suggesting that quorum-sensing molecules were
safe for in vivo applications. Control mice harboring non-
engineered CHO-K1 cells did not contain elevated serum
SEAP levels in the presence and absence of IM-2-SCB1.
IM-2-SCB1-responsive SEAP expression pro®les in mice
resembled those observed in vitro with the same batch of
Table 2. Expression characteristics of stable CHO-SCA and CHO-SCA-SEAP clones in the presence and absence of IM-2-SCB1
CHO-SCA
Clone no. 15 16 35 38
±IM-2-SCB1 8.8 6 2.9 6.1 6 0.6 6.8 6 0.3 6.7 6 1.0
+IM-2-SCB1 0.13 6 0.02 0.10 6 0.12 0.15 6 0.08 0.15 6 0.03
CHO-SCA-SEAP
Clone no. 10 16 63 109
±IM-2-SCB1 8.4 6 0.4 5.2 6 0.2 3.0 6 0.1 13.7 6 0.3
+IM-2-SCB1 0.67 6 0.06 0.09 6 0.02 0.17 6 0.15 0.17 6 0.17
CHO-SCA cell clones were transfected with pWW124 (PSPA-SEAP-pA) and grown for 48 h in the presence and absence of IM-2-SCB1 before measuring
SEAP activity (in U/l). CHO-SCA-SEAP cell clones were grown for 48 h with (10 mg/ml) and without IM-2-SCB1 before SEAP assays.
Figure 5. Regulation characteristics of CHO-SCA35-SEAP16 transgenic for
QuoRex-controlled SEAP expression. (A) IM-2-SCB1-adjustable SEAP
production. CHO-SCA35-SEAP16 cells (66 000 cells/ml) were cultivated for
48 h at indicated IM-2-SCB1 concentrations prior to quanti®cation of
SEAP production. (B) Expression kinetics of CHO-SCA35-SEAP16 cells
cultivated in the presence and absence of IM-2-SCB1 for 48 h.
(C) Reversibility of QuoRex-controlled transgene expression. Two cultures
(66 3 106 CHO-SCA35-SEAP16 cells/ml) were grown initially in the
presence and absence of IM-2-SCB1. At 48 h intervals the IM-2-SCB1
status was reversed (±IM-2-SCB1 ® +IM-2-SCB1 ® ±IM-2-SCB1; +IM-2-
SCB1 ® ±IM-2-SCB1 ® +IM-2-SCB1). SEAP production was monitored
during the entire cultivation.
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microencapsulated cells, thereby con®rming the in vivo com-
patibility of the QuoRex system (Fig. 6).
DISCUSSION
Pharmacological control of transgene expression is a current
priority in therapeutic engineering of mammalian cells to
titrate levels of desired protein pharmaceuticals in gene
therapy scenarios, or to reprogram preferred cell phenotypes
for tissue engineering (6,10,34±38).
Quorum-sensing systems enabling coordination of gene
expression within and between prokaryotic populations rep-
resent a vast reservoir of small-molecule response regulators,
which could be adopted for use as heterologous mammalian
gene regulation systems (19,22). As proof of principle we
converted a butyrolactone quorum-sensing regulator, which
controls antibiotics biosynthesis in S.coelicolor and
S.pristinaespiralis, for use as gene control systems in mam-
malian cells and mice (21,25). ScbR and SpbR, as well as their
cognate operators OscbR and OpapRI, are highly homologous
and recognize similar DNA sequences (20). Interestingly,
ScbR/SCA had stronger af®nities for heterologous OpapRI/
PSPA than for their cognate OscbR/PSCA modules which is
re¯ected in higher maximum expression levels of the SCA-
PSPA con®guration compared to the sister SCA-PSCA set-up. In
contrast to the ¯exibility in sequence recognition, the inter-
action of these quorum-sensing receptors with regulating
butyrolactones was highly speci®c. SCB1 exclusively inter-
acts with ScbR and ScbR-derived mammalian transactivators
but not with SpbR derivatives. Furthermore, SCA discrimin-
ates between the SCB1 diastereomers IM-2-SCB1 and VB-
SCB1 since IM-2-SCB1 enables ®ne-tuning of transgene
expression in mammalian cells with a lower concentration
window than VB-SCB1.
An important characteristic of the QuoRex system is its
in vivo compatibility showing negligible basal transcriptional
activity and IM-2-SCB1-adjustable target gene expression in
mice. Pioneering in vivo use of SCB1 suggested that this type
of butyrolactone is well tolerated in animals when adminis-
tered at regulating dosing regimes.
The prototype QuoRex system provides the ®rst evidence
that molecular interactions enabling bacteria to communicate
as multicellular systems can be successfully transferred to a
multicellular organism to ®ne-tune heterologous transgene
expression to desired levels. There are many bacterial
quorum-sensing systems, all consisting of protein receptors,
their cognate butyrolactones and operator sequences. Thus,
QuoRex represents a vast potential for development of a new
generation of small molecule-adjustable gene control systems
for clinical application (39).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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